China approved multiple innovative drugs to enter the market in 2025, with 30 of them already included in medical insurance.

In 2025, the National Medical Products Administration approved the listing of 76 innovative drugs, including 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines. This marked a new high in the quantity of approved drugs and highlighted the trend of diversified innovative therapies accelerating their market entry in China, greatly enriching the clinical treatment options for domestic patients. Among the 43 new drugs that can be applied for inclusion in the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List from January 1 to June 30, 2025, 30 drugs have successfully entered the national medical insurance list through negotiations. The coverage rate of the National Medical Insurance List for new drugs approved in the first half of 2025 can reach 70%, and these drugs can be reimbursed by medical insurance starting from January 1, 2026, benefiting patients in need and reducing their medication burden.